Effect to the Photobiomodulation in the Burning Mouth Syndrome
NCT05871580 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2024-04-18
Summary
Introduction: Burning mouth syndrome (BMS) is a pathology with a low prevalence, affecting between 0.1% and 3.7% of the general population, the ratio between women and men is between 3 and 7:1. It is clinically characterized by a burning pain sensation, recurrent daily for more than 2 hours a day, persistent for more than 3 months and in a way that increases throughout the day and decreases at night, without presenting clinically evident causal lesions on the surface of the oral mucosa, nor changes in clinical sensory tests.
The description of the symptomatology varies according to the patient and may be related especially to psychogenic factors.
Patients report dry mouth/xerostomia and taste alterations, such as metallic or bitter taste. The most frequent location is on the tongue (tip and lateral borders), but it can also include the anterior palate, gingiva and lips.
Since the etiopathogenic factors that produce BMS are not clear, it is difficult to make advances in therapy. The available treatments aim to control the multiple factors related to BMS, thus reducing the symptoms described by patients. Among them, the literature describes low level laser photobiomodulation.
The success of the use of low level lasers for treatments in oral medicine is due to their biomodulatory activity and their ability to penetrate tissues. The analgesic action of laser radiation is due to the inhibition of nociceptive mediators and the release by the Central Nervous System (CNS) of endogenous analgesic substances such as endorphins, which hinders the transmission of the painful stimulus.
It has been verified that low power laser radiation therapy can be effective in reducing symptoms in patients with BMS. Importantly, low power laser therapy is non-invasive, well tolerated by patients.
Objectives: To confirm the hypothesis that the application of low power laser in the areas of oral burning can improve the symptomatology of BMS.
Material and methods: We propose a clinical study in 38 patients with idiopathic BMS, prospective, randomized, double-blind.
The study universe will be constituted by patients attended at the Oral Medicine, Oral Surgery and Implantology Unit of the Faculty of Dentistry of the University of Santiago de Compostela (USC).
The Hospital Anxiety and Depression Scale (HADS), quality of life (OHIP-14) and subjective sensation of dry mouth xerostomia inventory (XI) questionnaires will be applied to all the patients, and the amount of saliva will be quantitatively determined by means of the unstimulated global saliva test (TSG-I) using a millimetric absorbent paper strip, at the beginning, at the end of treatment and at the re-evaluation at two and six months.
Conditions
- Burning Mouth Syndrome
- Quality of Life
- Anxiety Depression
- Dry Mouth
Interventions
- RADIATION
-
Low frequency laser activated photobiomodulation
Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients. * apex tongue: 3 points * lateral edge of the tongue: 4 points * tongue dorsum: 10 points * jugal mucosa: 8 points * labial mucosa: 5 points * hard palate: 8 stitches * soft palate: 3 stitches * gingiva or alveolar mucosa: 3 stitches per sextant. Time of 30 seconds in each application point, with dosage: 3 J/point.
- OTHER
-
Low frequency laser photobiomodulation inactive
The same protocol as the activated group
Sponsors & Collaborators
-
University of Santiago de Compostela
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-05-12
- Primary Completion
- 2023-10-30
- Completion
- 2024-01-15
Countries
- Spain
Study Locations
More Related Trials
-
Identification of Pathophysiological Pathways and Therapeutic Targets in Primary Stomatodynia by Salivary Metabolomics
NCT04704128 ·Status: COMPLETED
-
Inflammatory Markers in Saliva of Patients With Burning Mouth Syndrome
NCT06217731 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Melatonin in Burning Mouth Syndrome (BMS)
NCT02580734 ·Status: COMPLETED ·Phase: NA
-
Burning Mouth Syndrome: Effects of Occlusal Splint Therapy
NCT07344909 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Burning Mouth Syndrome: Symptoms and Management
NCT07016555 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome
NCT00862576 ·Status: COMPLETED
-
Therapeutic Options for Treatment of Burning Mouth Syndrome
NCT04475614 ·Status: COMPLETED ·Phase: NA
-
The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study
NCT01754740 ·Status: COMPLETED ·Phase: NA
-
Neurogenic Mechanisms in Burning Mouth Syndrome
NCT00875537 ·Status: COMPLETED ·Phase: NA
-
Photobiomodulation on the Salivary Glands of Patients With Xerostomia Induced by the Use of Benzodiazepines
NCT05443022 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Impact of Alpha Lipoic Acid Efficacy in Burning Mouth Syndrome
NCT05729529 ·Status: UNKNOWN ·Phase: NA
-
Photobiomodulation in Salivary Production of Patients With Xerostomy
NCT03632096 ·Status: UNKNOWN ·Phase: PHASE2
-
Salivary Melatonin Levels and Sleep Quality in Patients With Burning Mouth Syndrome
NCT05309681 ·Status: COMPLETED
-
Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
NCT02066896 ·Status: COMPLETED ·Phase: NA
-
Reducing Patient Memory Recall in the Burning Mouth Patient Population
NCT05819697 ·Status: RECRUITING
-
Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome
NCT04884503 ·Status: COMPLETED ·Phase: PHASE2
-
Alpha Lipoic Acid for Burning Mouth
NCT00387543 ·Status: COMPLETED
-
Burning Mouth Disorder (BMD) - A Neuropathic Pain Disorder
NCT00504387 ·Status: UNKNOWN
-
Effect of Photobiomodulation on ph and Salivary Flow
NCT05413993 ·Status: COMPLETED ·Phase: NA
-
Photobiomodulation In Treatment Of Xerostomia In Type Ii Diabetic Patients
NCT06703372 ·Status: COMPLETED ·Phase: NA
-
Salivary Markers in Patients With Xerostomia
NCT03156569 ·Status: COMPLETED
-
Acupuncture Combined With Hydroxychloroquine
NCT06432101 ·Status: COMPLETED ·Phase: NA
-
Interest of Auriculotherapy in the Treatment of Xerostomia
NCT04222478 ·Status: RECRUITING ·Phase: NA
-
Topical Management of Xerostomia With Dry Mouth Products
NCT03611283 ·Status: COMPLETED ·Phase: NA
-
Effects of Photobiomodulation in Salivary Analysis of Chronic Renal Failure Patients
NCT03647813 ·Status: COMPLETED ·Phase: PHASE2